{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:53:36Z","timestamp":1786118016478,"version":"build-2736575974"},"reference-count":39,"publisher":"Informa UK Limited","issue":"14","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung and Blood Institute","doi-asserted-by":"crossref","award":["T32HL116324"],"award-info":[{"award-number":["T32HL116324"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2017,6,1]]},"DOI":"10.2217\/fon-2017-0031","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T10:12:32Z","timestamp":1494497552000},"page":"1223-1232","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Venetoclax for the treatment of patients with chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"13","author":[{"given":"Jennifer","family":"Crombie","sequence":"first","affiliation":[{"name":"Write Affiliation text here. Department of Medical Oncology,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"Write Affiliation text here. Department of Medical Oncology,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.14553"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq373"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-585042"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159018"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154070"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"issue":"121","key":"e_1_3_3_13_1","first-page":"Abstract 119a","article-title":"Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (R) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study)","volume":"124","author":"Eichhorst B","year":"2014","unstructured":"Eichhorst B , FinkA-M, BuschRet al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (R) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood124(121), Abstract 119a (2014).","journal-title":"Blood"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.51"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3331.3331"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.330.330"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707133"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"issue":"3","key":"e_1_3_3_25_1","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson LE","year":"1996","unstructured":"Robertson LE , PlunkettW, McConnellK, KeatingMJ, McDonnellTJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia10(3), 456\u2013459 (1996).","journal-title":"Leukemia"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28281"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-688796"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.0981"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-414060"},{"issue":"4","key":"e_1_3_3_32_1","first-page":"484","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin\u2019s Lymphoma","volume":"57","author":"Salem AH","year":"2016","unstructured":"Salem AH , AgarwalSK, DunbarM, EnschedeSL, HumerickhouseRA, WongSL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin\u2019s Lymphoma. J. Clin.57(4), 484\u2013492 (2016).","journal-title":"J. Clin."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.741"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30012-8"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2033.2033"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2054.2054"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.637.637"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2044.2044"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.639.639"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.2217\/fon-2017-0031","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:56:12Z","timestamp":1786028172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":39,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,6,1]]}},"alternative-id":["10.2217\/fon-2017-0031"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0031","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}